Horizon Pharma (HZNP) has a weak-looking chart and indicators, along with a downgrade from TheStreet's Quant Ratings service. The stock could be headed below the horizon.
In this daily chart of HZNP, above, we can see the downtrend affecting the stock. Prices are below the declining 50-day and 200-day moving averages. The On-Balance-Volume (OBV) line has been pointed down since July 2015, and strongly suggests that sellers have been more aggressive with their holdings of HZNP -- volume has been heavier on days when HZNP has closed lower. In the lower panel, we find no serious bullish divergences from the momentum study that could foreshadow a turn to the upside.
In this longer-term weekly chart of HZNP, above, we can see the run up, and the run down, over the past three years. Prices are well below the declining 40-week moving average, which tends to reinforce the bear case for HZNP. The OBV line has been declining for months on this weekly time frame. The Moving Average Convergence Divergence (MACD) oscillator looks weak below the zero line. It would not surprise me if HZNP trends lower to next chart support around $10.